Coronavirus disease 2019

COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.

Catherine Nakidde Nzesei

BSc. | MA | MPH | PhD ongoing

Associate Director of Programmes

Catherine Nakidde Nzesei is the Centre’s Associate Director of Programmes – providing leadership and support to the Programmes Unit across all projects, teams and associates.

Catherine is a public health specialist with graduate training in public health, health promotion and international development. A recipient of the 2022 Commonwealth Scholarship, she embarked on a PhD in public pealth at UCL which is driven by her passion for health system strengthening – and building on previous work around Strengthening Health Professional Regulation in Uganda and Kenya. Catherine’s PhD examines systems and processes for continuous quality improvement of healthcare professional training.

Catherine’s professional interests revolve around leveraging impact from effective systems and empowering vulnerable population categories to enable them to fulfil their potential – whether in a professional, community or personal setting. Some of her previous work has focused on understanding the experiences of refugees and slum dwellers in the COVID-19 pandemic as well as health system resilience. Since inception, Catherine has directly supported for several Centre projects including those on Reproductive Maternal Newborn Child and Adolescent Health (RMNCAH), refugee health and wellbeing, Quality Improvement (QI) and livelihoods.